Lille Cedex

• Phase 2 Futibatinib in Combination with PD-1 Antibody-based Standard of Care in Solid Tumors Ended recruitment
  2023-507516-12-00 4 2024-05-08 Solid Tumors
• A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended recruitment
  2022-501234-37-00 7 2024-05-07 Solid Tumours
• A clinical study of V940 treatment and pembrolizumab in people with bladder cancer (V940-005) Ended recruitment
  2023-505658-17-00 4 2024-04-16 Muscle-invasive Urothelial Carcinoma
• Vitiligo treatment by targeting TYK2 mediated responses Ended recruitment
  2023-507451-30-00 4 2024-04-02 Vitiligo
• A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim … Ended recruitment
  2023-506183-13-00 4 2024-03-29 Alzheimer’s Disease
• A Study of Mirikizumab (LY3074828) in Pediatric Participants with Crohn’s Disease (AMAY) Ended recruitment
  2024-511472-32-00 5 2024-03-12 Crohn's Disease
• A study of continued treatment with regorafenib in participants with solid tumors who have participated in other Bayer studies Ended recruitment
  2023-507084-19-00 4 2024-03-07 Solid malignant tumors
• Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC): Evaluation of the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Co … Ended recruitment
  2022-502948-13-00 4 2024-03-01 Hepatocellular Carcinoma
• A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended recruitment
  2023-503288-40-00 5 2024-01-26 Unresectable or Metastatic Melanoma
• Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran … Ended recruitment
  2024-514876-41-00 9 2023-12-06 Higher-risk myelodysplastic syndromes untreated and ineligible for all
• A Phase 3, Open-label, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Chi … Ended recruitment
  2023-503294-37-00 5 2023-11-20 Osteogenesis Imperfecta
• Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib in G12C NSCLC Patients (RAMP203) Ended recruitment
  2023-505107-24-00 9 2023-11-14 Non-small cell lung cancer
• Trial of efficacy and safety of MC0518 versus best available therapy in patients with steroid-refractory acute graft versus host disease Ended recruitment
  2023-503952-28-00 4 2023-11-13 Steroid refractory Acute Graft versus host Disease
• A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’ … Ended recruitment
  2022-502966-26-01 5 2023-10-27 Sjögren’s syndrome
• A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD … Ended recruitment
  2022-501343-33-00 5 2023-10-18 Biochemically recurrent prostate cancer
• A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with T … Ended recruitment
  2023-508945-41-00 4 2023-10-11 Hepatocellular Carcinoma
• Study of safety and efficacy of Venetoclax in combination with Vidaza (Azacitidine) in higher-risk Chronic Myelomonocytic Leukemia (CMML) Ended recruitment
  2024-514878-53-00 4 2023-10-04 HMA-naïve, higher-risk (HR, defined as CPSS-mol risk intermediate-2 or
• A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe … Ended recruitment
  2022-501644-15-01 4 2023-09-28 Mild Cognitive Impairment due to Alzheimer's Disease Alzheimer's Disea
• Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate … Ended recruitment
  2022-502188-39-00 4 2023-09-27 Dermatitis atopic
• A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T … Ended recruitment
  2022-501346-30-00 5 2023-09-25 Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autolo
• SUrGery with or without dARolutamide in high-risk and/or locally advanced prostate cancer Ended recruitment
  2022-501518-67-00 4 2023-08-10 High-risk and/or locally advanced prostate cancer
• A study to test a medicine (fitusiran) injected under the skin for preventing bleeding episodes in male adolescent or adult participants wit … Ended recruitment
  2022-500221-33-01 5 2023-07-28 Hemophilia
• A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis Ended recruitment
  2024-510627-20-00 5 2023-07-28 Non-alcoholic Steatohepatitis (NASH) Cirrhosis
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com … Ended recruitment
  2022-501576-25-00 5 2023-07-07 Melanoma

Showing 409–432 of 681 trials